Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

DermalTherapy

Financiado

Membrane fusion mediated dermal allergy immunotherapy

In this project we aim to develop a new delivery platform for allergy vaccines with a high efficacy and a high safety profile combining membrane fusion-mediated delivery and microneedle-based dermal delivery. Background: Within t... ver más

31/08/2016

ULEI

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-08-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-PoC-2014: ERC Proof of Concept Grant

I+D

Cerrada hace 10 años

0% 100%

2 Participantes

ULEI

150.00K€ | Lider

NAIPES HERACLIO FOURNIER

525.87K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 15 meses Fecha Inicio: 2015-05-28
Fecha Fin: 2016-08-31

Líder del proyecto

UNIVERSITEIT LEIDEN

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto In this project we aim to develop a new delivery platform for allergy vaccines with a high efficacy and a high safety profile combining membrane fusion-mediated delivery and microneedle-based dermal delivery. Background: Within the ERC Starting Grant Direct Drug Delivery, I developed a method for the controlled fusion of liposomes with cells. A set of complementary peptide amphiphiles (coilK and coilE), able to form heterodimeric coiled coils, were shown to induce targeted and efficient fusion between two opposing membranes. More importantly, we have shown that this method of fusion can be applied to liposomes and to live cells. Since liposomes can be used as drug or vaccine carriers, this enables the direct delivery of these compounds into live cells. The Problem: Allergen-specific immunotherapy for treating allergies such as asthma is currently performed via chronic subcutaneous administration of allergen extracts to patients. Unfortunately, it requires monthly injections for several years to achieve the desired long-lasting immunological tolerance. These vaccinations are typically performed by intramuscular or subcutaneous injections, causing pain and stress. Therefore there is a need for a new and more efficient administration platform to achieve shorter, safer and more patient-friendly protocols. Our solution: Dermal delivery of vaccines offers a great potential, due to the large number of immune cells present in the skin. In order to increase the efficacy of current allergen-specific immunotherapy, it is our idea to use the membrane fusion heterodimeric coiled coil peptide pair to induce efficient cellular uptake and processing of a commercially used allergen (rBet v1) encapsulated in liposomes in order to increase its efficacy as an allergy vaccine.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores